Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer	Adnexal Diseases, Female Urogenital Diseases, Female Urogenital Diseases and Pregnancy Complications, Genital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, endocrine system disorder, female reproductive system disorder, female reproductive system neoplasm, gonadal disorder, malignant endocrine neoplasm, neoplasm, ovarian cancer, ovarian disorder, primary peritoneal carcinoma	Recruiting	Phase 2	2026-07-14		NCT04606914

2 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
AbbVie	340
University of Alabama at Birmingham	467

9 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Allegheny Health Network	Pittsburgh	United States	13
Mayo Clinic	Rochester	United States	664
Ohio State University	Columbus	United States	1
University of Alabama at Birmingham Womens & Infants Center	Birmingham	United States	2
University of California San Francisco	San Francisco	United States	80
University of Minnesota - Masonic Cancer Center	Minneapolis	United States	3
University of Mississippi Medical Center	Oxford	United States	1
University of Oklahoma	Oklahoma City	United States	28
University of Virginia	Richmond	United States	1